Figure 2: Anordrin inhibits tamoxifen-induced NAFLD as an estrogenic agent in mouse liver.
From: Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity
(a) Paraffin-embedded H&E sections (40x magnifications) of normal mouse liver treated by drugs for 109 days. TAM or ANO: mice were treated with tamoxifen or anordrin alone, respectively. TAM + ANO mice were treated with the combination of tamoxifen and anordrin. Blank, no drug was added to the food. (b) Statistical analysis of liver triglyceride (TG) content, as in (a); N = 12; **means P < 0.01. (c) The worst NAFLD syndrome is shown close to the capillary vessel in the mouse liver. (d) Statistical analyzing the square of Fatty area as in (c); N = 2 × 6; **means P < 0.01. (e) H&E staining liver sections of OVX mice. (f) Statistical analysis of liver triglyceride (TG) content, as in (e). **and ***mean P < 0.01 and P < 0.001: Two independent experiments with total twelve sections, for each time point, under the same conditions.
